Primecap Management CO Allogene Therapeutics, Inc. Transaction History

Primecap Management CO

$126 Billion
Q3 2025

A detailed history of Primecap Management CO transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Primecap Management CO holds 7,079,308 shares of ALLO stock, worth $8.71 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

7,079,308

Previous 5,719,140 23.78%

Holding current value

$8.71 Million

Previous $6.46 Million 35.84%

% of portfolio

0.01%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	BUY	$1.03 - $1.66 $1.4 Million - $2.26 Million	1,360,168 Added 23.78%	7,079,308 $8.78 Million
Q2 2025 Aug 11, 2025	BUY	$0.95 - $1.7 $747,935 - $1.34 Million	787,300 Added 15.96%	5,719,140 $6.46 Million
Q1 2025 May 09, 2025	BUY	$1.4 - $2.84 $6,300 - $12,780	4,500 Added 0.09%	4,931,840 $7.2 Million
Q4 2024 Feb 10, 2025	SELL	$1.84 - $3.22 $1.36 Million - $2.39 Million	-740,920 Reduced 13.07%	4,927,340 $10.5 Million
Q3 2024 Nov 08, 2024	SELL	$2.08 - $3.5 $4,089 - $6,881	-1,966 Reduced 0.03%	5,668,260 $15.9 Million

Q2 2024 Aug 09, 2024	BUY	$2.23 - $4.38 $494,703 - $971,659	221,840 Added 4.07%	5,670,226 $13.2 Million
Q1 2024 May 13, 2024	BUY	$2.92 - $5.63 $486,180 - $937,395	166,500 Added 3.15%	5,448,386 $24.4 Million
Q4 2023 Feb 09, 2024	SELL	$2.28 - $3.5 $5,699 - $8,750	-2,500 Reduced 0.05%	5,281,886 $17 Million
Q3 2023 Nov 13, 2023	SELL	$3.17 - $5.96 $1.12 Million - $2.1 Million	-352,300 Reduced 6.25%	5,284,386 $16.8 Million
Q2 2023 Aug 11, 2023	SELL	$4.53 - $6.74 $599,319 - $891,702	-132,300 Reduced 2.29%	5,636,686 $28 Million
Q1 2023 May 15, 2023	BUY	$4.92 - $8.21 $4.06 Million - $6.77 Million	825,070 Added 16.69%	5,768,986 $28.5 Million
Q4 2022 Feb 13, 2023	BUY	$5.62 - $11.11 $286,901 - $567,165	51,050 Added 1.04%	4,943,916 $31.1 Million
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $102,168 - $171,072	9,900 Added 0.2%	4,892,866 $52.8 Million
Q2 2022 Aug 11, 2022	SELL	$6.78 - $12.28 $157,974 - $286,124	-23,300 Reduced 0.47%	4,882,966 $55.7 Million
Q1 2022 May 11, 2022	BUY	$7.65 - $15.29 $1.87 Million - $3.74 Million	244,451 Added 5.24%	4,906,266 $44.7 Million
Q4 2021 Feb 11, 2022	BUY	$13.13 - $24.52 $13.9 Million - $25.9 Million	1,057,515 Added 29.34%	4,661,815 $69.6 Million
Q3 2021 Nov 12, 2021	BUY	$21.01 - $27.64 $572,942 - $753,742	27,270 Added 0.76%	3,604,300 $92.6 Million
Q2 2021 Aug 10, 2021	BUY	$23.49 - $35.8 $53.4 Million - $81.3 Million	2,271,630 Added 174.02%	3,577,030 $93.3 Million
Q1 2021 May 14, 2021	BUY	$25.79 - $39.02 $1.73 Million - $2.61 Million	67,000 Added 5.41%	1,305,400 $46.1 Million
Q4 2020 Feb 08, 2021	BUY	$25.24 - $43.45 $31.3 Million - $53.8 Million	1,238,400 New	1,238,400 $31.3 Million

Others Institutions Holding ALLO

# of Institutions

182

Shares Held

138M

Call Options Held

76.6K

Put Options Held

36.2K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $177M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Primecap Management CO with notifications on news.

Account

Primecap Management CO Allogene Therapeutics, Inc. Transaction History